<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3683">
  <stage>Registered</stage>
  <submitdate>2/11/2012</submitdate>
  <approvaldate>2/11/2012</approvaldate>
  <nctid>NCT01728324</nctid>
  <trial_identification>
    <studytitle>Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2</studytitle>
    <scientifictitle>A Phase III Randomised, Partially Double-blind and Placebo-controlled Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Chronic Genotype 1 Hepatitis C Infection in an Extended Population of Treatment na√Øve Patients That Includes Those Ineligible to Receive Peginterferon</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2012-003535-27</secondaryid>
    <secondaryid>1241.36</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis C, Chronic</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BI 207127-placebo: 8-week treatment
Treatment: drugs - Ribavirin: 24-week treatment
Treatment: drugs - BI 207127: 24-week treatment
Treatment: drugs - Faldaprevir: 24-week treatment
Treatment: drugs - Faldaprevir: 24-week treatment
Treatment: drugs - Ribavirin-placebo: 8-week treatment
Treatment: drugs - BI 207127: 24-week treatment
Treatment: drugs - Faldaprevir-placebo: 8-week treatment
Treatment: drugs - Faldaprevir: 16-week treatment
Treatment: drugs - Ribavirin: 16-week treatment
Treatment: drugs - RBV: 24-week treatment
Treatment: drugs - BI 207127: 16-week treatment

Experimental: Randomised 24-week arm - BI 207127 in combination with FDV and RBV for 24 weeks (randomised)

Experimental: Randomised 16-week arm - BI 207127-placebo, FDV-placebo and RBV-placebo for 8 weeks followed by BI 207127 in combination with FDV and RBV for 16 weeks (randomised)

Experimental: Allocated 24-week arm - BI 207127 in combination with FDV and RBV for 24 weeks (allocated to patients with compensated cirrhosis)


Treatment: drugs: BI 207127-placebo: 8-week treatment
8 weeks of placebo treatment

Treatment: drugs: Ribavirin: 24-week treatment
24 weeks of active treatment

Treatment: drugs: BI 207127: 24-week treatment
24 weeks of active treatment

Treatment: drugs: Faldaprevir: 24-week treatment
24 weeks of active treatment

Treatment: drugs: Faldaprevir: 24-week treatment
24 weeks of active treatment

Treatment: drugs: Ribavirin-placebo: 8-week treatment
8 weeks of placebo treatment

Treatment: drugs: BI 207127: 24-week treatment
24 weeks of active treatment

Treatment: drugs: Faldaprevir-placebo: 8-week treatment
8 weeks of placebo treatment

Treatment: drugs: Faldaprevir: 16-week treatment
16 weeks of active treatment

Treatment: drugs: Ribavirin: 16-week treatment
16 weeks of active treatment

Treatment: drugs: RBV: 24-week treatment
24 weeks of active treatment

Treatment: drugs: BI 207127: 16-week treatment
16 weeks of active treatment

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>SVR12 Rates With Historical Control - Sustained Virologic Response at Week 12 post-treatment (SVR12): Plasma Hepatitis C virus (HCV) RNA level &lt;25 IU/mL at 12 weeks after end of Treatment (EOT). SVR12, was assessed based on the observed HCV RNA result taken at least 10 weeks after treatment discontinuation. This definition was also applied to patients who discontinued treatment early: if the patient had HCV RNA undetected at least 10 weeks after stopping all treatment, they were considered a responder in the primary analysis. This is the primary analyses of the primary endpoint.
The number of participants analyzed are actually adjusted number of participant analyzed.</outcome>
      <timepoint>12 Week (post-treatment)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Comparisons of SVR12 Rates Across Treatment Arms - Sustained Virologic Response rates across treatment arms at Week 12 post-treatment (SVR12). This is the secondary analyses of the primary endpoint.</outcome>
      <timepoint>12 Week (post-treatment)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>SVR4: Plasma HCV RNA Level &lt;25 IU/mL at 4 Weeks After EOT. - Sustained Virologic Response rates across treatment arms at Week 4 post-treatment (SVR4): Plasma HCV RNA level &lt;25 IU/mL at 4 weeks after EOT.</outcome>
      <timepoint>4 weeks (after End Of Treatment)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>SVR24: Plasma HCV RNA Level &lt;25 IU/mL at 24 Weeks After EOT. - Sustained Virologic Response rates across treatment arms at Week 24 post-treatment (SVR24): Plasma HCV RNA level &lt;25 IU/mL at 24 weeks after EOT.</outcome>
      <timepoint>4 weeks (after End Of Treatment)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Prognostic Value of SVR12 Predicting SVR24 - The positive predictive value of SVR12 predicting SVR24 are the patients with an SVR12 (=YES) and the SVR24 was assessed.</outcome>
      <timepoint>24 Week (post-treatment)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          1. Chronic hepatitis C infection, diagnosed by positive anti-HCV antibodies and detected
             HCV RNA at screening

          2. HCV infection of sub-GT1b confirmed by genotypic testing at screening.

          3. HCV viral load =1,000 IU/mL at randomisation.

          4. Patients who have never been previously treated with any other HCV treatment regimen.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          1. HCV infection of mixed GT (1/2, 1/3, and 1/4) diagnosed by genotypic testing at
             screening.

          2. HCV infection of sub-GT1a, mixed GT1a/1b, or undefined GT1.

          3. Liver disease due to causes other than chronic HCV infection.

          4. HIV infection.

          5. Hepatitis B virus infection based on presence of HBs-Ag.

          6. Confirmed or suspected active malignancy or history of malignancy within the last 5
             years prior to screening.

          7. History of illicit drug abuse other than cannabis or chronic alcohol abuse within 12
             months prior to randomisation.

          8. Subject is not willing to comply with the precautionary measures to prevent
             photosensitivity (avoid excessive sun exposure and use sun block on a daily basis).

          9. Decompensated liver disease, or history of decompensated liver disease.

         10. Clinical evidence of unstable cardiovascular disease which may further decompensate
             due to anemia.

         11. Red blood cell disorders.

         12. Body weight &lt;40 kg or &gt;125 kg.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>496</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>1241.36.61005 Boehringer Ingelheim Investigational Site - Camperdown</hospital>
    <hospital>1241.36.61010 Boehringer Ingelheim Investigational Site - Kogarah</hospital>
    <hospital>1241.36.61009 Boehringer Ingelheim Investigational Site - New Lambton</hospital>
    <hospital>1241.36.61007 Boehringer Ingelheim Investigational Site - Randwick</hospital>
    <hospital>1241.36.61002 Boehringer Ingelheim Investigational Site - Herston</hospital>
    <hospital>1241.36.61004 Boehringer Ingelheim Investigational Site - Clayton</hospital>
    <hospital>1241.36.61001 Boehringer Ingelheim Investigational Site - Darlinghurst</hospital>
    <hospital>1241.36.61008 Boehringer Ingelheim Investigational Site - Heidelberg</hospital>
    <hospital>1241.36.61006 Boehringer Ingelheim Investigational Site - Melbourne</hospital>
    <postcode> - Camperdown</postcode>
    <postcode> - Kogarah</postcode>
    <postcode> - New Lambton</postcode>
    <postcode> - Randwick</postcode>
    <postcode> - Herston</postcode>
    <postcode> - Clayton</postcode>
    <postcode> - Darlinghurst</postcode>
    <postcode> - Heidelberg</postcode>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Li√®ge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Roeselare</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clichy Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Creteil</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Grenoble Cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 20</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Laurent du Var Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Aachen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dortmund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>D√ºsseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Erlangen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Esslingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>T√ºbingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Patras</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Rhodes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Antella (fi)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bisceglie (bat)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Palermo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pavia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pescara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>San Giovanni Rotondo (fg)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland NZ</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Barreiro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Coimbra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisboa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Badalona (Barcelona)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>L'Hospitalet Llobregat (BCN)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Malaga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Vigo (Pontevedra)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Edinburgh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Hull</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leicester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Newcastle upon Tyne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Oxford</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Plymouth</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boehringer Ingelheim</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of the study is to confirm efficacy and safety of treatment with 600 mg of BID BI
      207127 in combination with 120 mg QD FDV and RBV for 16 or 24 weeks in target chronically
      infected HCV GT1b treatment na√Øve patients, including patients with compensated cirrhosis.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01728324</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Boehringer Ingelheim</name>
      <address>Boehringer Ingelheim</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>